Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis. Sheridan J P, Robinson RR, Rose JW Expert Rev Clin Pharmacol. 2013 Dec 2. PMID: 24308792. Abstract CommentRecommendBookmarkWatch